The EMA's scientific advisory body, the committee for medicinal products for human use (CHMP), has given AbbVie and Genentech (a Roche company) the green light for conditional approval of their jointly developed chronic lymphocytic leukemia (CLL) product, Venclyxto (venetoclax). But both companies will need to carefully position the drug alongside their existing CLL therapies – AbbVie's Imbruvica (ibrutinib) and Roche's Gazyva – to avoid cannibalization of sales.
Furthermore, AbbVie will need to pursue label extensions quickly in CLL if Venclyxto is going to help prevent pending profit...






